With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.
TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space.
Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).
Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.
This webinar spotlighted the latest capabilities from Our Future Health, the UK’s largest health research programme, now offering imputed and geographic data, dispensed medication records, and direct participant recruitment pathways.
Brainomix earned top recognition in the Science category for its innovative approach to improving outcomes for patients affected by cardiovascular disease and stroke.
This blog explores the key investor insights, policy priorities, and technological breakthroughs shaping the future of UK TechBio, revealing how collaboration, talent, and data are driving the sector from innovation to global endurance.
New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.
Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.
Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months
Our latest TechBio: Future-ready biology report confirms a major structural shift in the UK life sciences sector: TechBio has moved from a niche field to the mainstream, accounting for over 40% of all UK biotech deals in recent years.
Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.'
It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch.
Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.
The BIA moves into a new era this week, amidst news from the US on tariffs for UK pharma, UK political party conferences underway and a change in leadership at GSK. It’s full steam ahead for BIA towards a busy Autumn, ensuring that the life science sector stays at the top of the government’s priority list and that our members are represented and connected.
In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.
In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.
